Attralus, Inc.
8
2
3
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
67%
2 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Role: lead
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Role: collaborator
A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
Role: lead
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
Role: collaborator
124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome
Role: collaborator
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
Role: lead
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Role: collaborator
A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
Role: lead
All 8 trials loaded